Destiny Pharma PLC 's (LON:DEST) chief executive Neil Clark talks to Proactive London's Polly Middlehurst about the company's focus on developing new anti-infectives for the prevention of infections.
Clark also discusses the government-funded COVID-19 product navel spray, part of a collaboration agreement with UK biotech SporeGen, to co-develop SporeGen's SPOR-COV product as a novel, preventive treatment.
Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Clark says they are "some great opportunities for quality assets that deliver solutions in this whole area of infection prevention".
